CLAIMS

VACCINE COMPOSITION CONTAINING TRANSFORMING GROWTH FACTOR ALPHA ($TGF\alpha$). IT USE IN MALIGNANT DISEASES THERAPY.

- 5 1 Vaccine composition containing self-TGF α or any derived or its combination with other EGF-R ligands, coupled with any carrier protein genetically or by chemical conjugation that contains an adjuvant, able to produce a specific immune response against the self-TGF α .
 - 2 Vaccine composition according to claim1 containing recombinant human TGFα.
 - 3 Vaccine composition according to claim1 wherein the carrier protein used is P64k.
- 4 Vaccine composition according to claim1 that contains a recombinant fusion protein between TGFα and P64k cloned in any expression vector system such as: mammalian cells, bacteria or yeast.
 - 5 Vaccine composition according to claim1 that contains a recombinant fusion protein between TGF α and P64k cloned in a expression vector of bacteria and expressed in E.coli.
- 6 Vaccine composition according to claim1 that contains a recombinant fusion protein between hTGF α and P64k cloned in a expression vector of bacteria that presents a genetic sequence coding for six histidines in the N-terminal end of P64k and expressed in E.coli.
 - 7 Vaccine composition according to claim1 that contains a chemical conjugated between $TGF\alpha$ and P64k.
 - 8 Vaccine composition according to claim1 that contains TGF α , EGF and P64k coupled by a chemical method.
 - 9 Vaccine composition according to claim1 that contains $TGF\alpha$, EGF and P64k in a recombinant fusion protein cloned in a expression vector of bacteria and expressed in E.coli.
 - 10 Vaccine composition that represents the mix of two vaccine preparations containing the chemical conjugated between P64k and TGF α or EGF respectively in the moment of the injection
 - 11 Vaccine composition that represents the mix of two vaccine preparations containing fusion proteins between the P64k and $TGF\alpha$ or EGF respectively in the moment of injection.
 - 12 Vaccine composition according to claim1 wherein the adjuvant is incomplete adjuvant of Freund.
 - 13 Vaccine composition according to claim1 wherein the adjuvant is Al(OH)₃.
 - 14 Immunization method with a vaccine composition according to claim 1 to 13, able to achieve specific antibodies against hTGF α .
 - 15 Treatment method according to claim 14, able to generate anti- hTGF α antibodies, capable of avoid the TGF α bind to its receptor in an in vitro experiment.
 - 16 Treatment method according to claim 14, able to generate anti-hEGF antibodies.
 - 17 Treatment method according to claim 14, able to generate anti- hTGF α antibodies, able of recognize TGF α in human tumor biopsies.
 - 18 Method of treatment of malignant diseases, such as epidermoide breast carcinomas, prostate, gastric, ovary epithelial cancer that express $TGF\alpha$ and other ligands of EGF-R, such as EGF, with a vaccine composition according to claims 1 to 13.

40